Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA, U1 small nuclear 17, pseudogene (RNU1-17P) is a genomic sequence classified as a pseudogene of the U1 small nuclear RNA (snRNA) gene family[1][4]. U1 snRNA is an essential component of the spliceosome, responsible for recognizing 5’ splice sites and initiating pre-mRNA splicing; however, pseudogenes like RNU1-17P traditionally have been considered non-functional genetic elements, as they typically contain sequence defects that prevent them from encoding functional RNA[4]. Recent studies suggest that some U1 snRNA pseudogenes are transcribed, can generate structurally variant RNAs, are incorporated into ribonucleoprotein complexes, and might play nuanced regulatory roles in specific cell types by influencing mRNA processing or acting as RNA decoys[4]. For RNU1-17P specifically, there is no known direct functional role, established disease association, or status as a therapeutic target; it does not interact with any known drugs and is considered non-coding and non-protein coding[1][4]. It is best classified as a non-coding RNA pseudogene found in the human genome.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U1 small nuclear 17, pseudogene (RNU1-17P).